Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2017 / Oct / Better Biopsies for Amyloidosis?
Neurology Clinical care Genetics and epigenetics Neurology Histology Screening and monitoring Technology and innovation Omics Research and Innovations

Better Biopsies for Amyloidosis?

A more rapid alternative for familial amyloid polyneuropathy diagnosis

By Roisin McGuigan 10/20/2017 1 min read

Share

Transthyretin-mediated amyloidosis (TTR) is an inherited condition that causes familial amyloid polyneuropathy (FAP), a disease that often proves fatal within just a decade. TTR-FAP is usually diagnosed by sural nerve biopsy and genetic testing – but it is a highly invasive procedure, and distribution of the amyloid aggregates needed to make a diagnosis can be patchy. And that’s why correct early diagnosis of the condition is uncommon (1).

Figure 1. A healthy skin biopsy. Image credit: Michael Polydefkis
Figure 2. A healthy skin biopsy; b. a skin biopsy from a patient with amyloidosis, with amyloid clumps in red. Image credit: Michael Polydefkis

A group of Johns Hopkins physicians have developed a modified approach using a skin punch biopsy, with the aim of creating a faster and relatively less invasive method of diagnosis. In a study of 30 FAP mutation carriers, 40 controls, and two patients with non-inherited amyloidosis, distal leg skin punch tissue samples stained with Congo red had 70 percent sensitivity and 100 percent specificity in diagnosing TTR-FAP (see Figure 1). The team also found that higher levels of amyloid aggregate were associated with loss of nerve fibers – which could lead to a new method of estimating disease severity and monitoring progression. They hope that, with a potential method for providing diagnostic and prognostic information less invasively, clinical trials of therapies could advance more quickly. The current method has only been tested on the most common FAP-causing TTR mutations, but the team hope that their work can be built upon. “If further studies confirm and extend what we have found, we may use the skin biopsy as a biomarker for disease severity. And we will be able to diagnose more patients sooner,” said Michael Polydefkis, professor of neurology and senior author of the study. “The good news is that drug companies are using our skin biopsy technique in ongoing clinical trials to monitor treatment success. (2)”

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. GJ Ebenezer et al., “Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy”, Ann Neurol, 82, 44–56 (2017). PMID: 28598015. Johns Hopkins Medicine, “Faster diagnosis of inherited and lethal nerve disease could advance search for new treatments”, (2017). Available at: http://bit.ly/2xgebL1. Accessed October 4, 2017.

About the Author(s)

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as an Associate Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

More Articles by Roisin McGuigan

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Event Tracking and Tracing with EMR
Clinical care
Event Tracking and Tracing with EMR

January 7, 2022

1 min read

Can tracking medical events, rather than patients, help us tackle diagnostic error?

2021: A Laboratory Medicine Roundup
Clinical care
2021: A Laboratory Medicine Roundup

January 18, 2022

3 min read

From transgender health care to the power of pathology podcasts, we take a look at our most popular articles of the last year

Not Just a Sample
Clinical care
Not Just a Sample

January 27, 2022

13 min read

Patient–pathologist interactions are vital – and both sides must work together to make the connection

Video: Not Just a Sample
Clinical care
Video: Not Just a Sample

January 28, 2022

1 min read

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.